ArticleAmerican journal of translational research2026
Associations between thyroid axis changes and glycemic improvement after weight loss in type 2 diabetes: a mediation analysis.
Article in American journal of translational research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo explore whether the favorable association between weight loss and glycemic improvement in patients with obesity and type 2 diabetes mellitus (T2DM) is partially mediated by weight loss-induced changes in the hypothalamic-pituitary-thyroid (HPT) axis, including alterations in thyroid-stimulating hormone (ΔTSH), free triiodothyronine (ΔFT3), and free thyroxine (ΔFT4).
methodsA total of 364 patients with obesity and T2DM who underwent bariatric surgery, glucagon-like peptide-1 receptor agonist (GLP-1RA) therapy, or standardized lifestyle intervention were enrolled in this retrospective real-world cohort study. Anthropometric, glycemic, and thyroid function indicators were measured at baseline and after a median follow-up of approximately 12 months.
resultsWeight loss interventions led to significant reductions in body weight, glycated hemoglobin (HbA1c), fasting plasma glucose (FPG), and homeostatic model assessment for insulin resistance (HOMA-IR), as well as a significant increase in homeostatic model assessment for β-cell function (HOMA-β) (all P < 0.001). Serum TSH and FT3 levels decreased markedly after intervention (both P < 0.001), whereas FT4 levels remained stable (P = 0.542). Changes in TSH and FT3 were significantly correlated with changes in HbA1c (ΔTSH: r = 0.319, P < 0.001; ΔFT3: r = 0.135, P = 0.010). The HPT axis exerted a significant total indirect mediating effect of 10.7% on the association between weight loss and HbA1c improvement (P = 0.032), with ΔTSH contributing 5.5% and ΔFT3 contributing 5.2% of the total effect. Subgroup analysis showed that the indirect mediating effect was more prominent in patients with higher baseline TSH levels.
conclusionChanges in thyroid axis markers, specifically reductions in TSH and FT3, significantly and indirectly mediate the improvement in glycemic control following weight loss interventions in T2DM patients. Although this mediating effect is modest in overall magnitude, it is augmented in individuals with elevated baseline TSH levels. These findings suggest a novel auxiliary mechanism underlying the metabolic benefits of weight loss mediated by HPT axis remodeling.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.